Neuronetics, Inc. STIM recently announced the FDA 510(k) clearance of NeuroStar Advanced Therapy for usage as a supplement to treat major depressive disorder (MDD) in adolescents aged between 15 and ...
Neuronetics, a medtech company focused on neurohealth disorders, today announced the FDA clearance of its NeuroStar Advanced Therapy for use as an adjust for the treatment of major depressive disorder ...
MALVERN, Pa., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for ...
MALVERN, Pa., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused on designing, developing and marketing products that improve ...
MALVERN, Pa., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life ...
Cigna's Evernorth unit is expanding coverage for Neuronetics' therapy for depression to adolescents. Neuronetics announced that Evernorth will offer coverage for its NeuroStar Transcranial Magnetic ...
MALVERN, Pa., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for ...
MALVERN, Pa., March 25, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback